Cargando…
Identification of PIKfyve kinase as a target in multiple myeloma
The cellular cytotoxicity of APY0201, a PIKfyve inhibitor, against multiple myeloma was initially identified in an unbiased in vitro chemical library screen. The activity of APY0201 was confirmed in all 25 cell lines tested and in 40% of 100 ex vivo patient-derived primary samples, with increased ac...
Autores principales: | de Campos, Cecilia Bonolo, Zhu, Yuan Xiao, Sepetov, Nikolai, Romanov, Sergei, Bruins, Laura Ann, Shi, Chang-Xin, Stein, Caleb K., Petit, Joachim L., Polito, Alysia N., Sharik, Meaghen E., Meermeier, Erin W., Ahmann, Gregory J., Armenta, Ilsel D. Lopez, Kruse, Jonas, Bergsagel, P. Leif, Chesi, Marta, Meurice, Nathalie, Braggio, Esteban, Stewart, A. Keith |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ferrata Storti Foundation
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271606/ https://www.ncbi.nlm.nih.gov/pubmed/31582538 http://dx.doi.org/10.3324/haematol.2019.222729 |
Ejemplares similares
-
“Direct to Drug” screening as a precision medicine tool in multiple myeloma
por: Bonolo de Campos, Cecilia, et al.
Publicado: (2020) -
Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4
por: Zhu, Yuan Xiao, et al.
Publicado: (2019) -
Revisiting checkpoint inhibitors for myeloma: maintenance after stem cell transplant
por: Meermeier, Erin W., et al.
Publicado: (2023) -
Transcriptional profiles define drug refractory disease in myeloma
por: Zhu, Yuan Xiao, et al.
Publicado: (2022) -
PIKfyve regulates melanosome biogenesis
por: Liggins, Marc C., et al.
Publicado: (2018)